In 1996, Arizona and California passed a law on medical cannabis for the first time, although Arizona later canceled the approval, so California paved the way. At the time of writing this report in 2016, 28 states and the District of Columbia had legalized the medical use of cannabis; 8 states had legalized the medical and recreational use of cannabis; and 16 other states had granted limited access to low-THC/CBD products (i.e., low-THC and high-CBD products). A recent national survey found that among current adult users, 10.5 percent reported using cannabis exclusively for medical purposes, and 46.6 percent reported mixed medical/recreational use (Schauer et al., 2016).
The first of these was an open and expanded oral cannabidiol access program without a concurrent control group in patients with severe and persistent childhood epilepsy, conducted in 11 epilepsy centers in the United States and conducted by Devinsky et al. and von Rosenberg et al. . Devinsky Green Roads CBD Review et al. reported in 162 patients aged 1 to 30 years; Rosenberg et al. it has been reported in 137 of these patients. The median monthly frequency of motor seizures was 30.0 (interquartile range 11.0–96.0) at baseline and 15.8 (IQ 5.6-57.6) during the 12-week treatment period.
An additional research in the primary literature since the review of Whiting et al. no additional studies have been identified. We then searched the primary literature to find studies on cannabinoids compared to the most commonly used antiemetics. A study conducted in 2007 examined cannabinoid therapy compared to the current generation of serotonin antagonist antiemetics as opposed to the dopamine D2 receptor antagonists used in the previous studies. This study of 64 patients examined the commonly used antiemetic drug ondansetron compared to dronabinol compared to the combination of the two for delayed chemotherapy-induced nausea and vomiting (Meiri et al., 2007).
Certain properties of CBD oil derived from the cannabis sativa plant have been studied in clinical trials. Everything has been studied, including its effect on Parkinson’s disease, the immune system, antioxidant properties, serotonin production, schizophrenia, Dravet syndrome, and the results show that CBD oil can support our health in many ways. In addition, they have not been evaluated by the FDA to determine what dosage is appropriate, how they might interact with other medications or foods, or whether they have dangerous side effects or other safety concerns. The absence of a concomitant placebo control group and the resulting potential for regression to the mean and other sources of distortion reduce the strength of the conclusions drawn from the results presented by Devinsky et al. , Rosenberg et al. , and Tzadok et al. about the effectiveness of cannabinoids in epilepsy.
A high-quality systemic review identified a single small study that found no effect of two cannabinoids administered as buccal aerosol on intraocular pressure (Whiting et al., 2015). However, to be effective, treatments aimed at the lowest intraocular pressure must lead to a continuous rather than a temporary reduction in intraocular pressure. To date, studies showing positive effects have shown only short-term benefits for intraocular pressure, suggesting a limited potential of cannabinoids in the treatment of glaucoma.